- Home
- RVI vs ORIC Comparison
RVI vs ORIC Comparison
Compare RVI & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RVI | ORIC |
|---|---|---|
| Founded | N/A | 2014 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 990.4M | 861.3M |
| IPO Year | 2026 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RVI | ORIC |
|---|---|---|
| Price | $35.77 | $8.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $19.73 |
| AVG Volume (30 Days) | 816.1K | ★ 1.7M |
| Earning Date | N/A | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.21 | $7.23 |
| 52 Week High | $77.39 | $14.93 |
Technical Indicators
Market Signals| Indicator | RVI | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 41.04 | 49.46 |
| Support Level | $24.27 | $7.60 |
| Resistance Level | $63.18 | $9.13 |
| Average True Range (ATR) | 4.50 | 0.58 |
| MACD | -2.29 | 0.07 |
| Stochastic Oscillator | 5.27 | 58.38 |
Price Performance
Historical ComparisonAbout RVI Robinhood Ventures Fund I Common Shares of Beneficial Interest
Robinhood Ventures Fund I is a closed-end investment company. The investment objective, the Fund will mainly invest, under normal circumstances, in a concentrated portfolio generally consisting of ten or more private companies that, in the view, are growing companies at the frontiers of their respective sectors and industries. The Fund operates as a single segment.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.